Drilldown: Medicines

25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allylescaline (1) · Apixaban (1) · Bromo-DragonFLY (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Escaline (1) · Methallylescaline (1) · Proscaline (1) · Rivaroxaban (1) · TMA-2 (1)

None (25) · Eliquis (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Xarelto (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) · '"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)

None (26) · '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) · '"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1)

None (26) · NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1)

None (26) · 2.5 mg, 5 mg tablets (1) · 2.5, 10, 15, 20 mg tablets (1)

None (26) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) · 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d (1)

None (25) · insufflated (1) · Oral (3) · PR (1)

None (25) · 45-75 min (oral) (1) · Peak anticoagulant effect 2-4 hours (1) · Peak anticoagulant effect 3-4 hours (1)

None (25) · 12 hours (1) · 24 hours (1) · 4-8 h (1)

None (25) · 5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' (1) · Not well characterized (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1)

None (25) · Not well characterized (1) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) · ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)

None (26) · Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (25) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)